Copyright
©The Author(s) 2024.
World J Clin Oncol. Jan 24, 2024; 15(1): 9-22
Published online Jan 24, 2024. doi: 10.5306/wjco.v15.i1.9
Published online Jan 24, 2024. doi: 10.5306/wjco.v15.i1.9
Protein | Organ | Function/mechanism | Ref. |
STEAP1 | Stomach | Promoting peritoneal metastasis of GC | [113] |
Regulated at the level of cap-dependent translation initiation by phosphorylated eIF4E in GC | [114] | ||
Increasing cell proliferation, migration, and invasion of GC, via the activation of AKT/FoxO1 pathway and epithelial-mesenchymal transition | [72] | ||
Colon/rectum | Inducing cytotoxic T lymphocytes to recognize colon cancer with STEAP1 by specific STEAP1 peptide | [81] | |
Reducing ROS and preventing apoptosis of CRC cells via NRF2 pathway | [115] | ||
Liver | Increased hepatic uptake of STEAP1 antibody-drug conjugates | [116] | |
Accelerating cell proliferation by targeting c-Myc in liver cancer cells | [100] | ||
STEAP3 | Colon/rectum | Increased in CRC, along with CTR1 to induce copper accumulation | [84] |
Facilitating iron uptake and resistance to iron deprivation-induced apoptosis under hypoferric condition | [86] | ||
Time-dependent change of STEAP3 during inflammatory activation, along with specific accumulation of Fe (II) in inflammatory-activated macrophages | [85] | ||
Increasing exosome secretion in CRC, which can be cleaved by RHBDD1 in a dose/activity dependent manner | [87] | ||
Protected by hypoxia-induced lncRNA STEAP3-AS1 by preventing m6A-mediated degradation of STEAP3 mRNA | [89] | ||
Liver | Decreased expression in liver, associated with the transition from cirrhosis to HCC | [117] | |
Increased in HCC cell nucleus, promoting proliferation via RAC1-ERK-STAT3 and RAC1-JNK-STAT6 signaling axes | [102] | ||
Ferroptosis-related differential gene in HCV-infected cirrhotic HCC, impaired by matrix stiffness | [105] | ||
STEAP4 | Stomach | Highly expressed in GC, associated with infiltration of immune cells | [73] |
Colon/rectum | Decreased in CRC and positively correlated with immune-related biomarkers | [118] | |
Highly induced in mouse models of colitis and inflammatory bowel disease patients, increasing ROS production in a hypoxia-dependent manner | [91] | ||
Induced by the inflammatory cytokine IL-17 to drive copper uptake, critical for colon tumor formation | [119] | ||
Liver | Lowly expressed in HCC, controlled by hypermethylation in STEAP4 promoter region | [109] | |
Inhibiting proliferation and metastasis of HCC through PI3K/AKT/mTOR pathway inhibition | [111] | ||
Low level in HCC, associated with advanced HCC stage, poor survival, and immunosuppressive microenvironment | [112] | ||
Stimulated by the inflammatory cytokine IL-6, through STAT3 and CCAAT/enhancer-binding protein alpha in liver | [106] | ||
Hepatic STEAP4 antagonizes HBx-mediated hepatocyte dysfunction by interacting with and decreasing the stability of HBx | [107] | ||
Therapeutic effect of recombinant FGF21 on NAFLD is performed by increasing hepatic STEAP4 to protect hepatocytes | [108] |
- Citation: Fang ZX, Chen WJ, Wu Z, Hou YY, Lan YZ, Wu HT, Liu J. Inflammatory response in gastrointestinal cancers: Overview of six transmembrane epithelial antigens of the prostate in pathophysiology and clinical implications. World J Clin Oncol 2024; 15(1): 9-22
- URL: https://www.wjgnet.com/2218-4333/full/v15/i1/9.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i1.9